<p>Sarepta Therapeutics, Inc. (NASDAQ:SRPT - 獲取免費報告) 的股價在週二的午盤交易中上漲了 3.5%。該股交易最高達到 $21.63，最後交易價格為 $21.9690。在交易中，共成交了 80,512 股，較平均交易量 5,986,445 股下降了 99%。該股此前收盤價為 $21.23。</p>
<p>獲取 <strong>Sarepta Therapeutics</strong> 的提醒：</p>
<h2>分析師升級與降級</h2>
<ul>
<li>Sarepta 在 2025 年面臨嚴峻挑戰——分析師仍然預測 179% 的上漲空間</li>
</ul>
<p>SRPT 一直是多份研究分析報告的主題。華爾街禪在 11 月 8 日的研究報告中將 Sarepta Therapeutics 的股票評級從 &#34;持有&#34; 下調至 &#34;賣出&#34;。美國銀行在 10 月 22 日的報告中將 Sarepta Therapeutics 的目標價從 $16.00 上調至 $18.00，並給予該公司 &#34;表現不佳&#34; 的評級。BMO Capital Markets 在 9 月 22 日的研究報告中將 Sarepta Therapeutics 的評級從 &#34;市場表現&#34; 上調至 &#34;跑贏大盤&#34;，並設定了 $50.00 的目標價。古根海姆在 11 月 5 日的研究報告中將 Sarepta Therapeutics 的目標價從 $22.00 下調至 $19.00，並給予該公司 &#34;買入&#34; 的評級。最後，Leerink Partners 在 9 月 9 日的研究報告中將 Sarepta Therapeutics 的目標價從 $12.00 上調至 $15.00，並給予該公司 &#34;市場表現&#34; 的評級。九位分析師對該股給予了買入評級，十五位給予了持有評級，六位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的平均評級為 &#34;持有&#34;，平均目標價為 $33.68。</p>
<p><strong>查看我們最新的 SRPT 股票分析</strong></p>
<h2>Sarepta Therapeutics 股價上漲 3.1%</h2>
<ul>
<li>Sarepta 因致死事件下跌 42%；市場關注 Solid Biosciences</li>
</ul>
<p>該公司的債務與股本比率為 0.78，速動比率為 1.79，流動比率為 2.95。該公司的 50 日移動平均價格為 $20.74，200 日移動平均價格為 $20.14。該公司的市值為 22.9 億美元，市盈率為 -7.29，貝塔值為 0.54。</p>
<p>Sarepta Therapeutics (NASDAQ:SRPT - 獲取免費報告) 最近在 11 月 3 日公佈了季度財報。這家生物技術公司報告的季度每股收益為 ($0.13)，低於市場共識預期的 $0.02，差距為 ($0.15)。該公司在本季度的收入為 $3.9936 億，低於分析師預期的 $3.3151 億。Sarepta Therapeutics 的淨利潤率為 -11.25%，股本回報率為 -4.85%。與去年同期相比，Sarepta Therapeutics 的季度收入下降了 14.5%。在去年同期，該公司每股收益為 $0.62。研究分析師平均預測 Sarepta Therapeutics, Inc. 在當前年度將發佈 2.67 的每股收益。</p>
<h2>內部人士買賣</h2>
<ul>
<li>製藥行業拋售：RSI 指標顯示的 3 只股票你不應忽視</li>
</ul>
<p>在其他 Sarepta Therapeutics 的新聞中，首席運營官 Ian Michael Estepan 於 12 月 16 日出售了 13,187 股該股票，交易價格為每股平均 $22.31，總價值為 $294,201.97。交易後，首席運營官持有該公司 193,300 股股票，價值約為 $4,312,523。這代表其持股比例下降了 6.39%。該交易已在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站訪問。公司內部人士持有該公司 7.60% 的股份。</p>
<h2>對 Sarepta Therapeutics 的對沖基金看法</h2>
<p>幾家大型投資者最近調整了對該股票的持有。iSAM Funds UK Ltd 在第三季度新建了約 $25,000 的 Sarepta Therapeutics 持倉。Ancora Advisors LLC 在第三季度將其在 Sarepta Therapeutics 的持倉增加了 200.0%。Ancora Advisors LLC 目前持有 1,500 股該生物技術公司的股票，價值 $29,000，此前在上個季度又購買了 1,000 股。Byrne Asset Management LLC 在第三季度新建了約 $33,000 的 Sarepta Therapeutics 持倉。Allworth Financial LP 在第三季度將其在 Sarepta Therapeutics 的持倉增加了 2,098.8%。Allworth Financial LP 目前持有 1,803 股該生物技術公司的股票，價值 $35,000，此前在上個季度又購買了 1,721 股。最後，Parallel Advisors LLC 在第三季度將其在 Sarepta Therapeutics 的持倉增加了 165.3%。Parallel Advisors LLC 目前持有 2,016 股該生物技術公司的股票，價值 $39,000，此前在上個季度又購買了 1,256 股。86.68% 的股票由機構投資者持有。</p>
<h2>Sarepta Therapeutics 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Sarepta Therapeutics, Inc 是一家生物製藥公司，專注於為罕見的神經肌肉疾病發現和開發精準基因治療。公司總部位於馬薩諸塞州劍橋，Sarepta 的核心專長在於設計針對 RNA 的療法和基因療法，以解決潛在的基因突變。公司的使命是通過創新的治療方式改變杜氏肌營養不良症 (DMD) 及相關疾病患者的治療模式。</p>
<p>Sarepta 的商業產品包括幾種已獲得美國批准的外顯子跳躍療法。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票超過 Sarepta Therapeutics</li>
<li>請勿刪除，請立即閲讀</li>
<li>投資者提醒：微型 “$3 人工智能奇蹟股票” 即將爆發</li>
<li>埃隆警告 “美國破產”。特朗普的計劃在此。</li>
<li>是否可以從資本利得税中扣除任何費用？</li>
<li>巴菲特、蓋茨和貝索斯悄然拋售股票——原因在這裏。</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Sarepta Therapeutics 嗎？</h2>
<p>在考慮 Sarepta Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Sarepta Therapeutics 並不在名單上。</p>
<p>雖然 Sarepta Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Sarepta醫療

<p>Sarepta Therapeutics（納斯達克代碼：SRPT）股票在午盤交易中上漲了 3.5%，達到 21.9690 美元。儘管上漲，但交易量明顯低於平均水平。分析師的評級意見不一，普遍持 “持有” 評級，平均目標價為 33.68 美元。近期有內部人士賣出股票和對沖基金活動的情況被提及。該公司報告了季度收入下降和負的每股收益，未能達到預期。Sarepta 專注於基因藥物的開發</p>

<p>Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report)'s stock price shot up 3.5% during mid-day trading on Tuesday . The stock traded as high as $21.63 and last traded at $21.9690. 80,512 shares changed hands during trading, a decline of 99% from the average session volume of 5,986,445 shares. The stock had previously closed at $21.23.</p>
<div class="lb-trans"><p>Sarepta Therapeutics, Inc. (NASDAQ:SRPT - 獲取免費報告) 的股價在週二的午盤交易中上漲了 3.5%。該股交易最高達到 $21.63，最後交易價格為 $21.9690。在交易中，共成交了 80,512 股，較平均交易量 5,986,445 股下降了 99%。該股此前收盤價為 $21.23。</p>
</div><p>Get <strong>Sarepta Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Sarepta Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級與降級</h2>
</div><ul>
<li>Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 在 2025 年面臨嚴峻挑戰——分析師仍然預測 179% 的上漲空間</li>
</ul>
</div><p>SRPT has been the topic of a number of research analyst reports. Wall Street Zen downgraded shares of Sarepta Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 8th. Bank of America boosted their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company an &#34;underperform&#34; rating in a report on Wednesday, October 22nd. BMO Capital Markets raised Sarepta Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $50.00 target price on the stock in a research report on Monday, September 22nd. Guggenheim lowered their price target on Sarepta Therapeutics from $22.00 to $19.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, November 5th. Finally, Leerink Partners raised their price objective on shares of Sarepta Therapeutics from $12.00 to $15.00 and gave the company a &#34;market perform&#34; rating in a research report on Tuesday, September 9th. Nine analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Hold&#34; and an average price target of $33.68.</p>
<div class="lb-trans"><p>SRPT 一直是多份研究分析報告的主題。華爾街禪在 11 月 8 日的研究報告中將 Sarepta Therapeutics 的股票評級從 &#34;持有&#34; 下調至 &#34;賣出&#34;。美國銀行在 10 月 22 日的報告中將 Sarepta Therapeutics 的目標價從 $16.00 上調至 $18.00，並給予該公司 &#34;表現不佳&#34; 的評級。BMO Capital Markets 在 9 月 22 日的研究報告中將 Sarepta Therapeutics 的評級從 &#34;市場表現&#34; 上調至 &#34;跑贏大盤&#34;，並設定了 $50.00 的目標價。古根海姆在 11 月 5 日的研究報告中將 Sarepta Therapeutics 的目標價從 $22.00 下調至 $19.00，並給予該公司 &#34;買入&#34; 的評級。最後，Leerink Partners 在 9 月 9 日的研究報告中將 Sarepta Therapeutics 的目標價從 $12.00 上調至 $15.00，並給予該公司 &#34;市場表現&#34; 的評級。九位分析師對該股給予了買入評級，十五位給予了持有評級，六位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的平均評級為 &#34;持有&#34;，平均目標價為 $33.68。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on SRPT</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 SRPT 股票分析</strong></p>
</div><h2>Sarepta Therapeutics Trading Up 3.1%</h2>
<div class="lb-trans"><h2>Sarepta Therapeutics 股價上漲 3.1%</h2>
</div><ul>
<li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 因致死事件下跌 42%；市場關注 Solid Biosciences</li>
</ul>
</div><p>The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 2.95. The business's 50 day moving average price is $20.74 and its 200-day moving average price is $20.14. The company has a market cap of $2.29 billion, a price-to-earnings ratio of -7.29 and a beta of 0.54.</p>
<div class="lb-trans"><p>該公司的債務與股本比率為 0.78，速動比率為 1.79，流動比率為 2.95。該公司的 50 日移動平均價格為 $20.74，200 日移動平均價格為 $20.14。該公司的市值為 22.9 億美元，市盈率為 -7.29，貝塔值為 0.54。</p>
</div><p>Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.15). The company had revenue of $399.36 million during the quarter, compared to analyst estimates of $331.51 million. Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. Sarepta Therapeutics's quarterly revenue was down 14.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.62 EPS. On average, research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.</p>
<div class="lb-trans"><p>Sarepta Therapeutics (NASDAQ:SRPT - 獲取免費報告) 最近在 11 月 3 日公佈了季度財報。這家生物技術公司報告的季度每股收益為 ($0.13)，低於市場共識預期的 $0.02，差距為 ($0.15)。該公司在本季度的收入為 $3.9936 億，低於分析師預期的 $3.3151 億。Sarepta Therapeutics 的淨利潤率為 -11.25%，股本回報率為 -4.85%。與去年同期相比，Sarepta Therapeutics 的季度收入下降了 14.5%。在去年同期，該公司每股收益為 $0.62。研究分析師平均預測 Sarepta Therapeutics, Inc. 在當前年度將發佈 2.67 的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣</h2>
</div><ul>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>製藥行業拋售：RSI 指標顯示的 3 只股票你不應忽視</li>
</ul>
</div><p>In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the transaction, the chief operating officer owned 193,300 shares of the company's stock, valued at approximately $4,312,523. This represents a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 7.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Sarepta Therapeutics 的新聞中，首席運營官 Ian Michael Estepan 於 12 月 16 日出售了 13,187 股該股票，交易價格為每股平均 $22.31，總價值為 $294,201.97。交易後，首席運營官持有該公司 193,300 股股票，價值約為 $4,312,523。這代表其持股比例下降了 6.39%。該交易已在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站訪問。公司內部人士持有該公司 7.60% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Sarepta Therapeutics</h2>
<div class="lb-trans"><h2>對 Sarepta Therapeutics 的對沖基金看法</h2>
</div><p>Several large investors have recently modified their holdings of the stock. iSAM Funds UK Ltd acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at about $25,000. Ancora Advisors LLC grew its position in shares of Sarepta Therapeutics by 200.0% in the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 1,000 shares during the last quarter. Byrne Asset Management LLC acquired a new position in Sarepta Therapeutics during the 3rd quarter worth approximately $33,000. Allworth Financial LP lifted its stake in Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 1,721 shares during the last quarter. Finally, Parallel Advisors LLC boosted its position in Sarepta Therapeutics by 165.3% in the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company's stock valued at $39,000 after buying an additional 1,256 shares in the last quarter. 86.68% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>幾家大型投資者最近調整了對該股票的持有。iSAM Funds UK Ltd 在第三季度新建了約 $25,000 的 Sarepta Therapeutics 持倉。Ancora Advisors LLC 在第三季度將其在 Sarepta Therapeutics 的持倉增加了 200.0%。Ancora Advisors LLC 目前持有 1,500 股該生物技術公司的股票，價值 $29,000，此前在上個季度又購買了 1,000 股。Byrne Asset Management LLC 在第三季度新建了約 $33,000 的 Sarepta Therapeutics 持倉。Allworth Financial LP 在第三季度將其在 Sarepta Therapeutics 的持倉增加了 2,098.8%。Allworth Financial LP 目前持有 1,803 股該生物技術公司的股票，價值 $35,000，此前在上個季度又購買了 1,721 股。最後，Parallel Advisors LLC 在第三季度將其在 Sarepta Therapeutics 的持倉增加了 165.3%。Parallel Advisors LLC 目前持有 2,016 股該生物技術公司的股票，價值 $39,000，此前在上個季度又購買了 1,256 股。86.68% 的股票由機構投資者持有。</p>
</div><h2>Sarepta Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Sarepta Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.</p>
<div class="lb-trans"><p>Sarepta Therapeutics, Inc 是一家生物製藥公司，專注於為罕見的神經肌肉疾病發現和開發精準基因治療。公司總部位於馬薩諸塞州劍橋，Sarepta 的核心專長在於設計針對 RNA 的療法和基因療法，以解決潛在的基因突變。公司的使命是通過創新的治療方式改變杜氏肌營養不良症 (DMD) 及相關疾病患者的治療模式。</p>
</div><p>Sarepta's commercial products include several exon-skipping therapies approved by the U.S.</p>
<div class="lb-trans"><p>Sarepta 的商業產品包括幾種已獲得美國批准的外顯子跳躍療法。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Sarepta Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Elon Warns “America Is Broke”. Trump’s Plan Inside.</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Sarepta Therapeutics</li>
<li>請勿刪除，請立即閲讀</li>
<li>投資者提醒：微型 “$3 人工智能奇蹟股票” 即將爆發</li>
<li>埃隆警告 “美國破產”。特朗普的計劃在此。</li>
<li>是否可以從資本利得税中扣除任何費用？</li>
<li>巴菲特、蓋茨和貝索斯悄然拋售股票——原因在這裏。</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Sarepta Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Sarepta Therapeutics 嗎？</h2>
</div><p>Before you consider Sarepta Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Sarepta Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Sarepta Therapeutics 並不在名單上。</p>
</div><p>While Sarepta Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Sarepta Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Sarepta Therapeutics（納斯達克代碼：SRPT）股價上漲 3.5% - 這是怎麼回事